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Abstract
We conducted a genome-wide association study of male breast cancer using 823 cases and 2,795 
controls of European ancestry with validation in independent sample sets totalling 438 cases and 
474 controls. A novel variant in RAD51B (14q24.1) was significantly associated with male breast 
cancer risk (P = 3.02 ×10−13, odds ratio (OR) = 1.57). TOX3 (16q12.1) was also a susceptibility 
locus (P = 3.87 ×10−15, OR = 1.50).
Male breast cancer accounts for 1% of all breast cancer diagnoses. Family history is a 
significant risk factor for male breast cancer; the relative risk of breast cancer for a female 
with an affected brother is approximately 30% higher than for a female with an affected 
sister1. Approximately 10% of male breast cancer cases are BRCA2 mutation carriers while 
BRCA1 mutation carriers are reported less frequently2. Predicated on the assumption that 
common variation contributes appreciably to the heritable risk of male breast cancer, and 
since investigation of risk alleles for breast cancer in men may provide novel insight into 
genetic susceptibility for the disease in females, we performed a genome-wide association 
study (GWAS).
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Using Illumina OmniExpress arrays (Illumina, San Diego CA) we genotyped 920 male 
breast cancer cases ascertained from the UK (n = 805) and US (n = 115) (Supplementary 
Methods; Supplementary Table 1). For controls we used publicly available data on 2,912 
individuals from the 1958 British Birth Cohort, genotyped on Illumina 1.2M DuoCustom 
arrays. After applying pre-specified quality control measures (Supplementary Methods; 
Supplementary Figure 1; Supplementary Tables 2a and 2b), we estimated odds ratios (ORs) 
and 95% confidence intervals (CI) for 447,760 autosomal SNPs with minor allele 
frequencies (MAF) ≥ 5% in 823 cases and 2,795 controls. Quantile-quantile plots of P-
values showed minimal inflation of test statistics, indicating that there was no substantial 
cryptic population substructure or differential genotyping between cases and controls 
(genomic control inflation factor λ = 1.05; Supplementary Figure 2).
A total of 17 SNPs, mapping to six independent genomic regions, showed evidence of 
association with male breast cancer at P ≤ 5.0 × 10−7(Supplementary Figure 3). We 
attempted to validate the most significantly associated SNP mapping to each of the six 
regions in 438 cases and 474 controls recruited from 12 case-control series (Supplementary 
Methods; Supplementary Table 1). In a combined analysis the associations of two SNPs, 
rs1314913 (P = 3.02 × 10−13, OR = 1.57) and rs3803662 (P = 3.87 × 10−15, OR = 1.50) 
attained genome-wide significance (Table 1; Supplementary Tables 3 & 4).
SNP rs1314913 localises to intron seven of the RAD51B gene (RAD51 homolog B) on 
chromosome 14q24.1 at 67,769,347 bp (NCBI build 36). It maps to the distal end of a 
linkage disequilibrium block of approximately 52 kb (Supplementary Figure 4). RAD51 
family members function in both mitotic and meiotic homologous recombination and in 
DNA double-strand break repair. rs999737, located in intron 10 of RAD51B, has previously 
been shown to be associated with risk of female breast cancer3. This SNP maps 
approximately 335 kb telomeric to rs1314913 and is separated from it by strong 
recombination hotspots (Figure 1a; Supplementary Figure 4). rs999737 and rs1314913 are 
only weakly correlated in the male breast cases (r2 = 0.02) and the HapMap CEU population 
(r2 = 0.006). To test formally for independence between rs1314913 and rs999737 we fitted a 
logistic regression model, using the discovery phase samples, adjusted for rs999737 in 
which the OR for rs1314913 was 1.54 (P = 1.04 × 10−9). Conversely the OR for rs999737, 
adjusted for rs1314913, was 0.93 (P = 0.25).
To provide further insight into the association at 14q24.1 we imputed genotypes in cases and 
controls using data from the 1,000 Genomes Project. Fifty-two imputed SNPs were more 
strongly associated with male breast cancer than rs1314913 and delineated an 85 kb cluster 
from 67.68 Mb to 67.77 Mb (Figure 1a; Supplementary Table 5). To examine if any directly 
genotyped or imputed SNPs annotated a putative transcription factor binding site or 
enhancer element we conducted a bioinformatic search of the region (Supplementary 
Methods). Seven associated SNPs, including rs1314913, were highly evolutionarily 
conserved (Supplementary Table 6). Analysis of ENCODE project data, including the Broad 
histone modification datasets for human mammary epithelial cells (HMECs), showed that 
two conserved SNPs, rs1314913 and an adjacent SNP, rs1316014, were located in a 
transcription factor-binding site lying within a DNAse hypersensitive site flanked by regions 
of high H3K4 mono/di-methylation and low tri-methylation, features that are characteristic 
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of enhancer elements (Supplementary Figures 5 and 6). In silico predictions are compatible 
with the minor alleles of both rs1314913 and rs1316014 abrogating the DNA binding sites 
of AP-1 and related transcription factors (Supplementary Figure 7). It is possible that the 
role of AP-1 in modulating estrogen signalling and transcription4 might explain the 
association between rs1314913 and male breast cancer.
We have previously shown in a much smaller study that rs3803662, a synonymous SNP in 
LOC643714 mapping to chromosome 16q12.1 at 51,143,812 bp, was associated with male 
breast cancer risk, albeit not at genome-wide levels of significance5. Here we provide robust 
confirmatory evidence of that association (Table 1). Examination of imputed data suggests 
that the association spans a 61 kb region from 51.09 Mb to 51.16 Mb and is proximal to 
LOC643174(Figure 1b), localising to the gene TOX3 (TOX high mobility group family 
member three).
Rare variants in two breast cancer susceptibility genes, BRCA2 and CHEK2, have larger 
ORs in males compared with females2,6 and we show here that this is also true for two 
common susceptibility alleles. Both rs1314913 and rs3083662 are striking in the magnitude 
of their effects. Comparing the breast cancer OR for rs3803662 in our data with the 
published estimate for females (OR = 1.20 [1.16–1.24])7, the effect was significantly greater 
in males (P = 7.76 × 10−5). Since rs1314913 is a novel breast cancer susceptibility variant 
there are no equivalent female estimates for comparison.
Variants at 24 loci have so far been shown to influence female breast cancer risk3,7–14. Their 
associations with male breast cancer are shown in Supplementary Table 7. In addition to 
rs3803662, SNPs at 2q35, 6q25.1, 10q21.2, 11q13.3, 12p11.22 were significantly associated 
at P< 0.05. Loci at 3p24.1, 9p21.3 and 14q24.1 showed borderline associations at P ≤ 0.1. 
There was no significant association, however, between variants at the FGFR2 locus on 
chromosome 10q26.13 and male breast cancer risk (rs2981582; OR = 1.07 [0.96–1.20]; P = 
0.21). This observation is surprising since male breast cancer is almost entirely estrogen 
receptor (ER) positive. rs2981582 is the SNP with the strongest known association with ER 
positive breast cancer in females15 and the power of our study to detect an allele with the 
same effect size as for female breast cancer at P ≤ 0.05 is close to 100%. rs3803662, 
however, is strongly associated with both ER negative and ER positive breast cancer in 
females15. Therefore the ER status of male breast cancers does not obviously explain the 
SNP associations.
These data provide evidence for low penetrance susceptibility to male breast cancer. Given 
the modest size of our study it is likely that additional risk variants can be identified by 
future GWAS.
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Figure 1. Association and recombination plots for the 14q24.1 and 16q12.1 loci
Directly genotyped SNPs from the discovery phase are represented as diamonds and 
imputed SNPs as circles. A larger diamond indicates the GWAS “hit” in each region. The 
strength of linkage disequilibrium between each SNP and the GWAS hit is indicated by the 
colour intensity of the symbol, from white (r2 = 0) to dark red (r2 = 1). Recombination rates, 
plotted in dark blue, are based on the HapMap CEU samples and genomic coordinates are 
based on NCBI build 36 of the human genome. Results are shown for the (a) 14q24.1 and 
(b) 16q12.1 loci. The location of rs999737 is indicated in bold at the distal end of RAD51B 
in the 14q24.1 plot.
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